A best evidence topic in perioperative care was written according to a structured protocol. The question addressed was 'Does ambroxol confer a protective effect on the lung in patients undergoing cardiac surgery or having lung resection?' A total of 247 papers were found using the reported search, of which 7 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers were tabulated. Several studies indicate that for patients with chronic obstructive pulmonary disease (COPD) who undergo cardiac surgery or upper abdominal surgery, perioperative ambroxol administration is associated with improved pulmonary function and reduced postoperative pulmonary complications (PPCs). In patients with pulmonary lobectomy, large-dose ambroxol treatment (1000 mg/day for 3 days) is correlated with reduced PPCs (6 vs 19%, P = 0.02), decreased postoperative hospital stay (5.6 vs 8.1 days, P = 0.02) and lower postoperative cost (2499 vs 5254 €, P = 0.04) compared with low-dose ambroxol treatment. Ambroxol also has a protective effect on the lungs during extracorporeal bypass, ameliorating inflammatory reaction and oxygen stress and preserving pulmonary surfactant. However, there is no evidence for any advantage of reducing PPCs after extracorporeal circulation. We conclude that perioperative application of ambroxol, a versatile mucoactive drug, particularly in high doses, is associated with lower PPCs, especially in high-risk patients with fundamental lung disease such as COPD. Large doses of ambroxol are correlated with even lower PPCs after lung resection. We recommend that routine intravenous ambroxol should be used in large doses in high-risk patients in the perioperative period to reduce the risk of PPCs.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You are seeing a 75-year old patient with moderately impaired left ventricular function and severe triple vessel coronary artery disease and a recent myocardial infarction, who has ongoing angina. He clearly needs surgery but his lung function is very poor due to a long smoking history and you are concerned that he is at significant risk of respiratory failure postoperatively. You discuss this with your anaesthetist and he suggests a course of high-dose Ambroxol pre-and postoperatively. You have never tried this strategy, so resolve to look it up in the literature.
SEARCH STRATEGY
Medline from 1950 to November 2013 using the Pubmed interface: ('ambroxol 
SEARCH OUTCOME
A total of 247 papers were found using the reported search. From these, seven papers were identified that provided the best evidence to answer the question. These are presented in Table 1 . Continued a day and 15 mg ambroxol three times a day on pulmonary function in patients with COPD who required urgent cardiac surgery. Pulmonary conditioning improved the forced expiratory volume in 1 s (FEV1) by 16% (P < 0.001). Predicted FEV1 increased from 48.3 ± 13.6% at baseline to 55.4 ± 16.1% after treatment (P < 0.001). Total resistance was reduced from 0.933 ± 0.418 to 0.631 ± 0.344 kPa s/l after PC (P = 0.004). The percentage of patients in GOLD stages III-IV was reduced from 55.6% at baseline to 27.8% after treatment. The authors concluded that short-term treatment with budenoside, salbutamol and ambroxol should be considered for patients with insufficiently controlled COPD. Refai et al. [3] studied the effect of high-dose ambroxol on the reduction of postoperative pulmonary complications (PPCs) after lobectomy in a randomized, controlled trial (RCT). They found Less quantity and better quality of sputum with easier expectoration, and greater reduction of cough intensity in Group A than in Group B (data not shown)
The authors concluded that ambroxol might be able to prevent acute respiratory distress syndrome development and limit the development of infection
The first randomized, controlled trial on this question that short-term perioperative treatment with high doses of intravenous ambroxol significantly reduced the overall incidence of PPCs (6 vs 19%, P = 0.02), decreasing the postoperative in-hospital stay (5.6 vs 8.1 days, P = 0.02) and the postoperative cost (2499 vs 5254 €, P = 0.04). Ulas et al. [4] studied the effect of ambroxol on lecithin/ sphingomyelin in BALF, arterial oxygen level and pulmonary function in patients without fundamental lung disease who underwent on-pump CABG. The authors reported similar lecithin/sphingomyelin in BALF and no significant increase in pulmonary function in patients given ambroxol. Only arterial oxygen pressure (PaO 2 ) on Postoperative Day 2 was significantly increased, compared with control cases (62.4 ± 7.1 vs 55.2 ± 6.4 mmHg, P < 0.05).
Zhou et al. [5] studied the effect of ambroxol on modulating systemic inflammation in patients with American Society of Anesthesiologists Grade II-III who received on-pump valve replacement. The authors found that ambroxol has a protective effect on lungs by ameliorating the systemic inflammation and increase of respiratory index, which was commonly seen after extracorporeal bypass surgery.
In a multicentre RCT, Fegiz et al. [6] focused on high-risk patients undergoing upper abdominal operations, which might be performed by cardiothoracic surgeons. The authors reported a significantly lower incidence of atelectasis (10.6 vs 23.9%, P < 0.05), a smaller decrease in PaO 2 and a trend towards less pneumonia (8.8 vs 12.4%, P > 0.05) in patients administrated intravenous high-dose ambroxol (1 g/day) for 6 consecutive days in the perioperative period compared with patients administered a placebo.
Marcatili et al. [7] studied the role of ambroxol on the endoalveolar surfactant level after extracorporeal circulation. They found that postoperative phospholipids in bronchoalveolar lavage in the ambroxol group were significantly higher than in the control group at 24 h (9.04 ± 0.40 vs 4.07 ± 0.34 µg/ml, P < 0.01) and at 8 days (12.35 ± 0.47 vs 6.24 ± 0.48 µg/ml, P < 0.01). They concluded that ambroxol increases the endoalveolar surfactant level after extracorporeal circulation and might play a role in reducing PPCs after extracorporeal circulation.
Romanini et al. [8] studied the effectiveness of ambroxol in reducing the surface tension after chest surgery. They found that a high dose of ambroxol (1 g/day) was associated with lower in-alveolar surface tension and better mucociliary clearance of the respiratory tract, thus leading to better re-expansion of the pulmonary parenchyma after surgery, which was indispensable for limiting PPCs.
CLINICAL BOTTOM LINE
Perioperative use of ambroxol, a versatile mucoactive drug, is associated with lower PPCs, especially in high-risk patients with chronic lung disease. Large-dose ambroxol treatment (1 g/day for 3 days) reduces PPCs in patients undergoing lung resection, compared with low-dose ambroxol treatment. Ambroxol also has a protective role on lungs during extracorporeal bypass. However, there is no evidence for any advantage of reducing PPCs after extracorporeal circulation. We recommend intravenous ambroxol use in high doses in high-risk patients in the perioperative period in order to reduce the risk of PPCs.
